title: Evolution of microglial activation in ischaemic core and peri-infarct regions after stroke: a PET study with the TSPO molecular imaging biomarker [((11))C]vinpocetine.
abstract: Although there is increasing evidence for microglial activation after an ischaemic stroke in the infarct core and the peri-infarct region, the "evolution" of the process in stroke patients is poorly known. Using PET and [((11))C]vinpocetine, we measured the regional changes of TSPO in the brain of nine ischaemic stroke patients up to 14weeks after the insult. Already a week after stroke there was an increased radioligand uptake, indicating the up-regulation of TSPO and the presence of activated microglia, in both the ischaemic core and the peri-infarct zone. This increased activation showed a steady decrease with post stroke time. The proportion between %SUV values in the peri-infarct zone and the ischaemic core increased with time. There were no time-dependent TSPO activity changes in other regions, not affected directly by the stroke. The present observations demonstrate that increased regional microglia activation, as a consequence of stroke, can be visualised with PET, using the TSPO molecular imaging biomarker [((11))C]vinpocetine. The evolution of this microglial activation shows a time dependent decrease the gradient of which is different between the peri-infarct zone and the ischaemic core. The findings indicate an increased microglial activation in the peri-stroke region for several weeks after the insult.
authors: Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, S-171 76 Stockholm, Sweden. balazs.gulyas@ki.se
authors: Balázs
authors: B
authors: Gulyás
authors: Miklós
authors: M
authors: Tóth
authors: Martin
authors: M
authors: Schain
authors: Anu
authors: A
authors: Airaksinen
authors: Adám
authors: A
authors: Vas
authors: Konstantinos
authors: K
authors: Kostulas
authors: Per
authors: P
authors: Lindström
authors: Jan
authors: J
authors: Hillert
authors: Christer
authors: C
authors: Halldin
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000378:metabolism; D002545:Brain Ischemia / Q000150:complications / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology; D002250:Carbon Radioisotopes; D059907:Functional Neuroimaging / Q000379:methods* / Q000706:statistics & numerical data; D006801:Humans; D007238:Infarction / Q000150:complications / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology; D008279:Magnetic Resonance Imaging / Q000379:methods / Q000706:statistics & numerical data; D008297:Male; D017628:Microglia / Q000000981:diagnostic imaging / Q000378:metabolism*; D008875:Middle Aged; D057054:Molecular Imaging / Q000379:methods / Q000706:statistics & numerical data; D009929:Organ Size; D049268:Positron-Emission Tomography / Q000379:methods / Q000706:statistics & numerical data; D011869:Radioligand Assay / Q000379:methods / Q000706:statistics & numerical data; D018079:Receptors, GABA / Q000378:metabolism*; D020521:Stroke / Q000150:complications / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology; D013997:Time Factors; D015854:Up-Regulation; D014748:Vinca Alkaloids
chemical_list: D015415:Biomarkers; D002250:Carbon Radioisotopes; D018079:Receptors, GABA; C499229:TSPO protein, human; D014748:Vinca Alkaloids; C013983:vinpocetine